Abstract
COVID-19 (COronaVIrus Disease firstly reported in December 2019) is a complex and heterogeneous disease whose clinical spectrum ranges from asymptomatic cases or with mild symptoms to severe acute respiratory distress syndrome, with/without heart and kidney involvement, especially in people with comorbidities. Treatment we use today is quite empirical, depending on the severity of the disease, associated risk factors and access to medication. In severe cases, a combination of potent anti-cytokine monoclonal antibodies associated to low-dose dexamethasone and remdesivir and/or favipiravir is recommended. Here, we review the clinical evidence and indications of main biologic therapy in the treatment of COVID-19 patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
